Key statistics
As of last trade ACADIA Pharmaceuticals Inc (DR6:DUS) traded at 20.44, -14.05% below its 52-week high of 23.78, set on Dec 22, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 20.44 |
|---|---|
| High | 20.44 |
| Low | 20.44 |
| Bid | 20.47 |
| Offer | 20.90 |
| Previous close | 20.77 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 170.49m |
| Free float | 168.23m |
| P/E (TTM) | 10.77 |
| Market cap | 4.19bn USD |
| EPS (TTM) | 2.28 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 08:31 GMT.
More ▼
Press releases
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
More ▼
